Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Milademetan and Fulvestrant in GATA3-mutant, ER-positive, HER2-negative Advanced or Metastatic Breast Cancer Patients: a Multicenter Phase II Trial

NCT05932667 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT05932667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05932667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Milademetan and Fulvestrant in GATA3-mutant, ER-positive, HER2-negative Advanced or Metastatic Breast Cancer Patients: a Multicenter Phase II Trial
Lead sponsor
Institut Curie
Phase
Phase 2
Overall status
Terminated
Start date
October 12, 2023
Completion date
November 30, 2023
Enrollment
1 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic breast cancer